Skip to main content

Advertisement

SpringerLink
Log in

Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis

  • Case Report
  • Published:
Modern Rheumatology

Abstract

We present two patients with rheumatoid arthritis (RA) who developed necrotizing crescentic glomerulonephritis (NCGN) during etanercept therapy. Both patients developed proteinuria and hematuria, and one progressed to renal failure. Renal biopsy revealed NCGN. In both patients, nephritis improved following discontinuation of etanercept and administration of prednisolone. Physicians should be aware of etanercept-induced GN in patients with RA on anti-tumor necrosis factor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bongartz T, Sutton A, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.

    Article  CAS  PubMed  Google Scholar 

  2. Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. Pathology annual. New York: Appleton-Century-Crofts; 1968. p. 145–86.

    Google Scholar 

  3. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Fred G, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–52.

    Google Scholar 

  4. Messiaen T, M’bappé P, Boffa JJ, Khayat R, Mougenot B, Rossert J, et al. MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis. Am J Kidney Dis. 1998;32:E6.

    Article  CAS  PubMed  Google Scholar 

  5. Qarni M, Kohan DE. Pauci-immune necrotizing glomerulonephritis complicating rheumatoid arthritis. Clin Nephrol. 2000;54:54–8.

    CAS  PubMed  Google Scholar 

  6. Obayashi M, Uzu T, Harada T, Yamato M, Takahara K, Yamauchi A. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol. 2003;7:275–8.

    Article  CAS  PubMed  Google Scholar 

  7. Yoshida A, Morozumi K, Suganuma T, Sugito K, Ikeda M, Oikawa T, et al. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis. Am J Nephrol. 1991;11:284–8.

    Article  CAS  PubMed  Google Scholar 

  8. Törnroth T, Skrifvars B. The development and resolution of glomerular basement membrane changes associated with subepithelial immune deposits. Am J Pathol. 1975;79:219–36.

    PubMed  Google Scholar 

  9. Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D’Agati VD, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009;4:299–308.

    Article  CAS  PubMed  Google Scholar 

  10. Taniguchi Y, Yorioka N, Kumagai J, Ito T, Yamakido M, Taguchi T. Myeloperoxidase antineutrophil cytoplasmic antibody-positive necrotizing crescentic glomerulonephritis and membranous glomerulonephropathy. Clin Nephrol. 1999;52:253–5.

    CAS  PubMed  Google Scholar 

  11. Kanahara K, Yorioka N, Nakamura C, Kyuden Y, Ogata S, Taguchi T, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission. Intern Med. 1997;36:841–6.

    Article  CAS  PubMed  Google Scholar 

  12. Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234–8.

    CAS  PubMed  Google Scholar 

  13. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–6.

    Article  CAS  PubMed  Google Scholar 

  14. Kemp E, Nielsen H, Petersen LJ, Gam AN, Dahlager J, Horn T, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol. 2001;55:87–8.

    CAS  PubMed  Google Scholar 

  15. Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol. 2008;27:261–4.

    Article  PubMed  Google Scholar 

  16. Simms R, Kipgen D, Dahill S, Marshall D, Rodger RS. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis. 2008;51:e11–4.

    Article  PubMed  Google Scholar 

  17. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–51.

    Article  Google Scholar 

  18. Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 26(3) Suppl 49:S23–9.

  19. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.

    Article  CAS  PubMed  Google Scholar 

  20. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119:296–305.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Kayoko Kaneko, Toshihiro Nanki, Tadashi Hosoya, Fumitaka Mizoguchi & Nobuyuki Miyasaka

  2. Department of Pharmacovigilance, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8519, Japan

    Toshihiro Nanki

Authors
  1. Kayoko Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshihiro Nanki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadashi Hosoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fumitaka Mizoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobuyuki Miyasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshihiro Nanki.

About this article

Cite this article

Kaneko, K., Nanki, T., Hosoya, T. et al. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol 20, 632–636 (2010). https://doi.org/10.1007/s10165-010-0333-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0333-3

Keywords

Search

Navigation